Translate the text from English to Welsh.



 
Today, following a review of all the evidence, the Joint Committee for Vaccination and Immunisation (JCVI) has published its recommendations to further expand the COVID\-19 vaccination programme to children aged five to 11 who are not considered to be at clinical risk. 


As I set out in my statement yesterday (15 February), I have accepted this advice and am grateful to the JCVI for its insight, considerations and expertise, which has proved so invaluable throughout this pandemic.  


At the current time, the JCVI considers the balance of potential benefits and harms is in favour of offering a vaccination to all children aged five to 11\.


It advises two 10 mcg doses of the Pfizer\-BioNTech Paediatric COVID\-19 vaccine (Comirnaty®) is offered with an interval of at least 12 weeks between doses. Children this young must have the opportunity of being accompanied by a parent or guardian during vaccination and the absence of any age priority within the advice makes it easier for eligible siblings to be vaccinated at the same time.


The JCVI advises this is a non\-urgent offer with the aim of increasing this age group’s immunity in advance of any potential future waves of COVID\-19 and will enable children to benefit from as much time in school as possible. It also advises the offer should not displace the delivery of other paediatric non\-COVID\-19 or COVID\-19 immunisation programmes.


Delivery of paediatric non\-COVID\-19 immunisation programmes across all ages should receive due attention, particularly where vaccine coverage has fallen behind due to the COVID\-19 pandemic and where there is evidence of health inequalities. Once common illnesses are now rare in the UK because of immunisation.


I would urge children, young people and their parents and carers to follow Public Health advice and ensure they are fully immunised to protect them from potentially serious diseases, such as measles and meningitis.


This advice is considered by JCVI as a one\-off pandemic responseprogramme. As the COVID\-19 pandemic moves further towards endemicity in the UK, the JCVI will review whether, in the longer term, an offer of vaccination to this, and other paediatric age groups, continues to be advised.


NHS Wales has been planning for this scenario for a number of weeks. There is work in train to ensure the necessary immunisation and clinical guidance is in place, and there is factual and trusted information on the Public Health Wales website for children and parents to inform their decision, before health boards will be ready to implement.


I would encourage families to begin to have conversations about the offer and whether to take up the vaccine when it becomes available.







Translation:


 
Ar ôl adolygu’r holl dystiolaeth, mae’r Cyd\-bwyllgor ar Imiwneiddio a Brechu (JCVI) heddiw wedi cyhoeddi ei argymhellion i ehangu’r rhaglen frechu COVID\-19 ymhellach i blant 5 i 11 oed nad ydynt yn perthyn i grŵp risg clinigol.


Fel y nodais yn fy natganiad ddoe (15 Chwefror), rwyf wedi derbyn y cyngor hwn ac rwy’n ddiolchgar i’r JCVI am ei dystiolaeth, ei ystyriaethau a’i arbenigedd, sydd wedi bod mor werthfawr drwy gydol y pandemig.


Ar hyn o bryd, ar sail cydbwyso’r manteision a’r niwed posibl, mae’r JCVI o blaid cynnig y brechlyn i bob plentyn 5 i 11 oed.


Mae’n cynghori bod dau ddos 10 mcg o’r brechlyn COVID\-19 Pediatrig Pfizer\-BioNTech (Comirnaty®) yn cael eu cynnig, gyda bwlch o 12 wythnos o leiaf rhwng y ddau ddos. Rhaid rhoi’r cyfle i blant mor ifanc â hyn gael rhiant neu warcheidwad gyda nhw yn ystod y brechiad. Nid yw’r cyngor yn cynnwys blaenoriaethu unrhyw oedrannau penodol o fewn y grŵp oedran dan sylw, felly bydd yn haws i frodyr a chwiorydd cymwys gael eu brechu ar yr un pryd.


Mae’r JCVI yn cynghori cynnig y brechiadau drwy gynllun llai brys, gyda’r nod o gynyddu imiwnedd y grŵp oedran hwn cyn unrhyw donnau COVID\-19 posibl yn y dyfodol, gan alluogi plant i fanteisio ar gymaint o amser â phosibl yn yr ysgol. Mae hefyd yn cynghori na ddylai’r cynnig hwn ddisodli’r gwaith o gyflwyno rhaglenni imiwneiddio pediatrig eraill, pa un a ydynt gysylltiedig â COVID\-19 ai peidio.


Dylid rhoi sylw dyledus i’r gwaith o gyflwyno rhaglenni imiwneiddio pediatrig eraill nad ydynt yn gysylltiedig â COVID\-19 i bob oedran, yn enwedig pan fo lefelau brechu yn is na’r disgwyl oherwydd pandemig COVID\-19 a phan fo tystiolaeth o anghydraddoldeb iechyd. Mae afiechydon a fu unwaith yn gyffredin nawr yn brin yn y DU oherwydd brechu.


Byddwn i’n annog plant, pobl ifanc a’u rhieni a’u gofalwyr i ddilyn y cyngor Iechyd Cyhoeddus a sicrhau eu bod wedi’u brechu’n llawn i’w diogelu rhag clefydau a all fod yn ddifrifol, fel y frech goch a llid yr ymennydd.


Mae’r JCVI yn ystyried mai rhaglen untro fydd hon er mwyn ymateb i’r pandemig. Wrth i bandemig COVID\-19 ddod yn fwy endemig yn y DU, bydd y JCVI yn adolygu a fydd yn parhau i gynghori bod y brechlyn yn cael ei gynnig i’r grŵp hwn ac i grwpiau pediatrig eraill yn y tymor hirach.


Mae GIG Cymru wedi bod yn cynllunio ar gyfer hyn ers sawl wythnos. Mae gwaith ar y gweill i sicrhau bod y canllawiau imiwneiddio a chlinigol angenrheidiol ar gael, a bod gwybodaeth ffeithiol a dibynadwy ar wefan Iechyd Cyhoeddus Cymru i blant a rhieni ei hystyried wrth wneud eu penderfyniad, cyn y bydd byrddau iechyd yn barod i weithredu’r rhaglen.


Byddwn i’n annog teuluoedd i ddechrau sgyrsiau am y cynnig ac ystyried a ydynt am fanteisio ar y brechlyn pan fydd ar gael.